Cathie's Ark Logo
Verve Therapeutics Inc Logo

ARKK Holdings of Verve Therapeutics (VERV) - Updated Daily

Gene TherapyGenomicsCRSPR Gene Editing
Date
Direction
Shares
Fund Weight
Fund
December 19, 2022
BUY38.421k0.0106%ARKK
December 16, 2022
BUY5.759k0.0016%ARKK
December 15, 2022
BUY37.163k0.0104%ARKK
December 14, 2022
BUY4.067k0.0013%ARKK
December 12, 2022
BUY46.155k0.0145%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
0.3%$913.90m
🏋🏿‍♂️Weight Rank In ARKK🌏Country
26🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
35
🎫ARK Ownership Percent
2.48%
Description
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.
Website
www.vervetx.com

Other ETFs That Hold VERV

Ticker
NameWeight
ARKGARK Genomic Revolution ETF2.46%
GNOMGlobal X Genomics & Biotechnology ETF1.1%
XBISPDR® S&P Biotech ETF0.82%
ARKKARK Innovation ETF0.36%

Research Notes and Commentary for VERV

No Research Notes Found for VERV